Dr. Thomas E. Ragole, MD
Neurology (Neurology Physician)
12401 E 17th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Colorado School of Medicine, Aurora (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 173
Licensed in Colorado since 2020, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Colorado School of Medicine, Aurora
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CO license DR.0064958 (first issued 2020; active) · OR license MD192817
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 173
- Services billed
- 366
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 49 | 37 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 33 | 32 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 32 | 21 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 23 | 23 |
| Established patient office or other outpatient visit, 30-39 minutes | 21 | 18 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 15 | 14 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 13 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Aurora, CO | 75 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 43 |
| Pregabalin Other prescribers in Aurora, CO | 30 |
| Mycophenolate Mofetil Other prescribers in Aurora, CO | 19 |
| Pyridostigmine Bromide Other prescribers in Aurora, CO | 15 |
| Baclofen Other prescribers in Aurora, CO | 15 |
| Ketorolac Tromethamine Other prescribers in Aurora, CO | 15 |
| Topiramate Other prescribers in Aurora, CO | 14 |
| Methylprednisolone Sodium Succ (methylprednisolone sod succ) | 14 |
| Promethazine Hcl Other prescribers in Aurora, CO | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $3,704 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $2,450 |
|---|---|
| UCB, Inc. | $1,240 |
| Cadwell Industries, Inc | $13.61 |
| Consulting Fee | $3,490 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $200 |
| Food and Beverage | $13.61 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Jul 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,450 |
| UCB, Inc. Aug 28, 2025 | Consulting Fee Rystiggo · Neurology | $1,040 |
| UCB, Inc. Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) Zilbrysq · Neurology | $200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $36,539 in research payments for these studies, mostly to the institutions running them.
- A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Argenx US, Inc. - A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.